Literature DB >> 17710290

Effect of enamel matrix proteins on the treatment of intrabony defects: a split-mouth randomized controlled trial study.

Daniela Chambrone1, Ivan Munhoz Pasin, Marina Clemente Conde, Claudio Panutti, Silvia Carneiro, Luiz Antonio Pugliesi Alves de Lima.   

Abstract

The objective of this split-mouth, double-blind, randomized controlled trial was to compare the clinical effect of treatment of 2- or 3-wall intrabony defects with open flap debridement (OFD) combined or not with enamel matrix proteins (EMP). Thirteen volunteers were selected with one pair of or more intrabony defects and probing pocket depth (PPD) > or = 5 mm. All individuals received instructions regarding oral hygiene and were submitted to scaling and root planing. Each participant received the two treatment modalities: test sites were treated with OFD and EMP, and control sites received only OFD. After 6 months, a significant reduction was observed in PPD for the EMP group (from 6.42 +/- 1.08 mm to 2.67 +/- 1.15 mm) and for the OFD group (from 6.08 +/- 1.00 mm to 2.00 +/- 0.95 mm) (p < 0.0001), but with no significant difference between groups (p = 0.13). A significant gain in relative attachment level (RAL) was observed in both groups (EMP: from 13.42 +/- 1.88 mm to 10.75 +/- 2.26 mm, p < 0.001; OFD: from 12.42 +/- 1.98 mm to 10.58 +/- 2.23 mm, p = 0.013), but with no significant difference between groups (p = 0.85). Gingival recession (GR) was higher in the EMP group (from 1.08 +/- 1.50 mm to 2.33 +/- 1.43 mm; p = 0.0009) than in the OFD group (from 0.66 +/- 1.15 mm to 1.16 +/- 1.33 mm; p = 0.16), but this difference was not significant (p = 0.06). In conclusion, the results showed that OFD combined with EMP was not able to improve treatment of intrabony defects compared to OFD alone.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17710290     DOI: 10.1590/s1806-83242007000300009

Source DB:  PubMed          Journal:  Braz Oral Res        ISSN: 1806-8324


  4 in total

Review 1.  Enamel matrix derivative (Emdogain(R)) for periodontal tissue regeneration in intrabony defects.

Authors:  Marco Esposito; Maria Gabriella Grusovin; Nikolaos Papanikolaou; Paul Coulthard; Helen V Worthington
Journal:  Cochrane Database Syst Rev       Date:  2009-10-07

2.  Hopeless tooth? Prognosis and comprehensive treatment. A case report.

Authors:  Mihaela Maria Grigorie; Ioana Suciu; Daniela Zaharia; Ecaterina Ionescu; Mihaela Chirila; Monica Voiculeanu
Journal:  J Med Life       Date:  2021 Mar-Apr

3.  Platelet-rich plasma plus bioactive glass in the treatment of intra-bony defects: a study in dogs.

Authors:  Marcelo Diniz Carvalho; Fabrícia Ferreira Suaid; Mauro Pedrine Santamaria; Marcio Zaffalon Casati; Francisco Humberto Nociti; Antonio Wilson Sallum; Enilson Antônio Sallum
Journal:  J Appl Oral Sci       Date:  2011 Jan-Feb       Impact factor: 2.698

4.  Two-year randomized clinical trial of enamel matrix derivative treated infrabony defects: radiographic analysis.

Authors:  Mariana Schutzer Ragghianti Zangrando; Daniela Chambrone; Ivan Munhoz Pasin; Marina Clemente Conde; Cláudio Mendes Pannuti; Luiz Antônio Pugliesi Alves de Lima
Journal:  BMC Oral Health       Date:  2014-12-04       Impact factor: 2.757

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.